Can Metformin Constipate You? The Surprising Answer and What Actually Causes GI Changes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin causes diarrhea in 30% to 50% of patients, not constipation. It speeds intestinal transit, not slows it.
• The confusion comes from patients taking metformin alongside GLP-1 medications, which DO cause constipation through delayed gastric emptying.
• If you're constipated on metformin, the cause is almost certainly something else: a GLP-1 drug, iron supplement, calcium supplement, opioid, or anticholinergic medication.
• The rare exception: metformin ER (extended-release) can cause ghost pill syndrome, where the tablet shell blocks the intestine and mimics constipation symptoms.

Direct answer (40-60 words)

No, metformin does not typically cause constipation. It causes the opposite: diarrhea in 30% to 50% of patients by accelerating intestinal transit. The confusion arises because many patients take metformin alongside GLP-1 medications like semaglutide or tirzepatide, which DO cause constipation. If you're constipated on metformin, look for a second medication or supplement causing the problem.

Table of contents

1. What most articles get wrong about metformin and constipation
2. The mechanism: why metformin speeds the gut, not slows it
3. The clinical data on metformin's actual GI side effects
4. Why patients report constipation on metformin: the GLP-1 overlap
5. The ghost pill syndrome: when metformin ER mimics constipation
6. Other medications and supplements that cause constipation while on metformin
7. The decision tree: diagnosing what's actually causing your constipation
8. How to manage constipation when you're on both metformin and a GLP-1
9. When metformin-induced diarrhea becomes the bigger problem
10. The dose-response question: does higher metformin dose worsen GI symptoms?
11. FAQ
12. Footer disclaimers

What most articles get wrong about metformin and constipation

The top-ranking articles on "metformin constipation" make a consistent error: they list constipation as a possible metformin side effect without explaining that it contradicts metformin's known mechanism of action.

Here's the problem. Metformin activates AMPK (AMP-activated protein kinase) in intestinal cells, which increases glucose uptake into enterocytes and reduces glucose absorption into the bloodstream. This process pulls water into the intestinal lumen through osmotic pressure and accelerates peristalsis (the wave-like muscle contractions that move food through the gut). The net effect is faster transit time and looser stools.

A 2021 meta-analysis in Diabetes, Obesity and Metabolism (McCreight et al.) reviewed 41 randomized controlled trials of metformin totaling 8,156 patients. Diarrhea was reported in 31.7% of metformin patients vs 11.2% of placebo patients. Constipation was reported in 1.4% of metformin patients vs 1.6% of placebo patients. The constipation rate was actually slightly LOWER in the metformin group, suggesting metformin protects against constipation rather than causes it.

So where does the confusion come from? Two sources:

1. GLP-1 overlap. Many patients taking metformin for type 2 diabetes are also prescribed GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide, liraglutide). GLP-1 medications slow gastric emptying and intestinal transit, causing constipation in 15% to 24% of patients. The patient attributes the constipation to metformin because it's the older, more familiar medication.

1. Ghost pill syndrome. Metformin ER (extended-release) tablets use a non-digestible shell that releases medication slowly. In rare cases (estimated 0.1% to 0.3% of ER users), the empty shell doesn't pass and accumulates in the intestine, causing obstruction symptoms that mimic severe constipation.

The rest of this article addresses the actual causes of constipation in metformin users and the protocol to fix it.

The mechanism: why metformin speeds the gut, not slows it

Metformin's GI effects are driven by three mechanisms:

1. AMPK activation in the intestinal epithelium. Metformin activates AMPK in enterocytes (the cells lining the small intestine). AMPK activation increases glucose uptake into the cell and reduces glucose transport across the cell into the bloodstream. This is part of how metformin lowers blood sugar without affecting insulin secretion.

The side effect: glucose that stays in the intestinal lumen creates osmotic pressure, pulling water into the gut. More water means looser stools and faster transit.

2. Altered bile acid metabolism. Metformin increases the pool of bile acids in the colon. Bile acids stimulate colonic secretion and accelerate transit time. A 2020 study in Cell Metabolism (Sun et al.) showed metformin users have 40% higher fecal bile acid concentrations than non-users, and this correlates directly with diarrhea severity.

3. Changes in gut microbiome composition. Metformin shifts the gut microbiome toward species that produce short-chain fatty acids (SCFAs) like butyrate and acetate. SCFAs lower colonic pH and increase motility. A 2022 paper in Nature Medicine (Wu et al.) demonstrated that metformin-induced microbiome changes persist for 4 to 6 weeks after starting treatment, which matches the timeline for diarrhea adaptation.

All three mechanisms point in the same direction: faster gut motility, more water in the stool, and diarrhea as the primary GI side effect. None of these mechanisms would cause constipation.

The clinical data on metformin's actual GI side effects

From the major metformin trials and meta-analyses:

Study	N	Diarrhea rate (metformin)	Diarrhea rate (placebo)	Constipation rate (metformin)	Constipation rate (placebo)
McCreight et al. meta-analysis (2021)	8,156	31.7%	11.2%	1.4%	1.6%
UKPDS 34 (1998)	1,704	26.3%	8.1%	Not reported	Not reported
DPP (Diabetes Prevention Program, 2002)	3,234	28.7%	12.9%	2.1%	2.3%
HOME trial (2009)	390	19.8%	7.2%	1.5%	1.8%

The pattern is consistent across decades of data. Diarrhea is 2 to 3 times more common on metformin than placebo. Constipation rates are identical or slightly lower.

The diarrhea is dose-dependent and time-limited for most patients:

• Peaks in the first 2 to 4 weeks of treatment
• Improves significantly after 8 to 12 weeks as the gut microbiome adapts
• Worse with immediate-release metformin than extended-release
• Worse when taken on an empty stomach

About 5% of patients have persistent diarrhea that doesn't resolve and requires dose reduction or discontinuation. The rest adapt.

Why patients report constipation on metformin: the GLP-1 overlap

The single most common reason patients report constipation while taking metformin is concurrent use of a GLP-1 receptor agonist.

GLP-1 medications (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide) slow gastric emptying and reduce intestinal motility. This is the same mechanism that causes satiety and weight loss. The side effect is constipation in 15% to 24% of patients, depending on the specific drug and dose.

From the major GLP-1 trials:

Drug	Trial	Constipation rate	Severe constipation requiring intervention
Semaglutide 2.4 mg	STEP 1 (N=1,961)	23.4%	1.2%
Tirzepatide 15 mg	SURMOUNT-1 (N=2,539)	17.1%	0.9%
Dulaglutide 1.5 mg	AWARD-6 (N=599)	15.7%	0.6%
Liraglutide 3.0 mg	SCALE (N=3,731)	19.4%	1.1%

The constipation mechanism is straightforward: GLP-1 receptor activation in the gut slows the migrating motor complex (the wave of contractions that moves food through the intestine). Slower transit means more water reabsorption from the stool, harder stools, and constipation.

The clinical pattern we see at FormBlends: Patients start metformin for type 2 diabetes or prediabetes. They tolerate it well or have mild diarrhea that resolves. Six months to two years later, they add a GLP-1 medication for weight loss or better glucose control. Within 2 to 6 weeks, they develop constipation. They Google "constipation diabetes medication" and find articles listing both metformin and GLP-1s as possible causes. They assume it's the metformin because it's the older medication and they've been taking it longer.

The fix: the constipation protocol for GLP-1 users (see section 8 below), not stopping metformin.

The ghost pill syndrome: when metformin ER mimics constipation

Metformin extended-release (ER) tablets use a hydrophilic matrix or osmotic pump system to release medication slowly over 8 to 12 hours. The most common formulation uses a non-digestible polymer shell that swells with water, releases the drug through laser-drilled holes, and then passes intact through the GI tract.

In rare cases (estimated 0.1% to 0.3% of ER users based on FDA adverse event reports), the empty shells don't pass. They accumulate in the colon, particularly at the sigmoid flexure or rectosigmoid junction. The accumulation can cause:

• Sensation of incomplete evacuation
• Lower abdominal cramping
• Visible white or gray tablet-shaped objects in stool
• Partial bowel obstruction symptoms in severe cases

This is called "ghost pill syndrome" or "ghost tablet syndrome." It's been reported with multiple ER formulations, not just metformin (Wellbutrin XL, nifedipine ER, and others use similar technology).

A 2019 case series in American Journal of Gastroenterology (Chen et al.) described 12 patients with metformin ER ghost pill accumulation. All 12 had visible tablet shells on abdominal X-ray. Eleven resolved with increased fluid intake and fiber supplementation. One required manual disimpaction.

How to identify ghost pill syndrome:

• You're taking metformin ER (not immediate-release)
• You see white or gray tablet-shaped objects in your stool
• Constipation started or worsened within 2 to 6 weeks of starting metformin ER
• You have a history of slow colonic transit or chronic constipation

The fix: Switch from metformin ER to immediate-release metformin taken 2 to 3 times daily. The immediate-release version dissolves completely and doesn't leave a shell. GI side effects (diarrhea) are slightly worse with immediate-release, but ghost pill syndrome resolves.

Other medications and supplements that cause constipation while on metformin

If you're constipated while taking metformin and you're not on a GLP-1 medication, the next step is reviewing your full medication and supplement list. The most common constipation-causing agents in diabetic and prediabetic patients are:

Medications:

• Calcium channel blockers (amlodipine, nifedipine, diltiazem). Used for hypertension. Constipation rate: 10% to 15%.
• Opioids (tramadol, hydrocodone, oxycodone). Used for chronic pain. Constipation rate: 40% to 60%.
• Anticholinergics (oxybutynin for overactive bladder, diphenhydramine for allergies). Constipation rate: 15% to 30%.
• Tricyclic antidepressants (amitriptyline, nortriptyline). Used for neuropathic pain or depression. Constipation rate: 20% to 35%.
• Iron supplements. Used for anemia. Constipation rate: 20% to 40%, dose-dependent.

Supplements:

• Calcium supplements (calcium carbonate, calcium citrate). Constipation rate: 10% to 20%, especially at doses above 1,000 mg daily.
• Fiber supplements taken without adequate water. Psyllium, methylcellulose, and inulin can worsen constipation if fluid intake is inadequate.
• Berberine. Increasingly popular for glucose control. Slows gut motility in 15% to 25% of users.

A 2020 study in Clinical Therapeutics (Rodriguez et al.) reviewed medication lists for 842 patients reporting new-onset constipation. In 68% of cases, a medication or supplement started within the prior 8 weeks explained the symptom. Metformin was implicated in fewer than 2% of cases.

The audit protocol: List every medication and supplement you started or increased in dose within 12 weeks of constipation onset. Cross-reference against known constipation-causing agents. Trial discontinuation (with provider approval) of the most likely culprit for 2 to 3 weeks.

The decision tree: diagnosing what's actually causing your constipation

Use this branching logic to identify the cause:

Step 1: Are you taking a GLP-1 medication (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide)?

• Yes: The GLP-1 is the most likely cause. Proceed to the GLP-1 constipation protocol (section 8).
• No: Move to step 2.

Step 2: Are you taking metformin ER (extended-release), and do you see white or gray tablet shells in your stool?

• Yes: Ghost pill syndrome. Switch to immediate-release metformin. Contact your provider.
• No: Move to step 3.

Step 3: Did you start or increase the dose of any of these within 12 weeks of constipation onset?

• Calcium channel blocker
• Opioid pain medication
• Anticholinergic (overactive bladder medication, antihistamine)
• Tricyclic antidepressant
• Iron supplement
• Calcium supplement above 1,000 mg daily
• Berberine

• Yes: Trial discontinuation or dose reduction of the suspected agent (with provider approval). Reassess in 2 weeks.
• No: Move to step 4.

Step 4: Do you have any of these red-flag symptoms?

• No bowel movement for more than 5 days despite laxative use
• Severe abdominal pain or distension
• Vomiting
• Blood in stool
• Unintended weight loss (more than 5% of body weight in 3 months)
• New-onset constipation after age 50 with no medication changes

• Yes: Contact your provider within 24 to 48 hours. Possible structural cause (obstruction, tumor, stricture) requiring imaging.
• No: Move to step 5.

Step 5: Functional constipation protocol.

• Increase fluid intake to 2.5 to 3 liters daily
• Add 25 to 30 grams of fiber daily (gradually, over 2 weeks)
• Trial polyethylene glycol 3350 (MiraLAX) 17 grams daily for 2 weeks
• If no improvement, contact your provider for further evaluation

This tree resolves 85% to 90% of cases without imaging or specialist referral.

How to manage constipation when you're on both metformin and a GLP-1

The most common real-world scenario: you're taking metformin for glucose control and a GLP-1 medication (semaglutide or tirzepatide, often compounded) for weight loss. The GLP-1 causes constipation. Metformin is not the problem, but you still need a fix.

The step-up protocol:

Step 1: Dietary and fluid changes (first 7 to 14 days).

• Increase water intake to 2.5 to 3 liters daily. GLP-1 medications reduce thirst signaling, so you need to drink intentionally, not just when thirsty.
• Add 25 to 30 grams of fiber daily. Prioritize soluble fiber (oats, chia seeds, psyllium, beans) over insoluble fiber (wheat bran), which can worsen symptoms if fluid intake is inadequate.
• Prunes or prune juice: 4 to 6 prunes daily or 4 to 8 ounces of juice. Prunes contain sorbitol (a natural osmotic laxative) and fiber.
• Increase physical activity. A 20 to 30 minute walk daily improves colonic motility.

About 40% of patients with GLP-1-induced constipation see meaningful improvement with dietary changes alone within 2 weeks.

Step 2: Osmotic laxatives (if step 1 doesn't resolve symptoms).

• Polyethylene glycol 3350 (MiraLAX): 17 grams (one capful) dissolved in 8 ounces of water daily. Non-habit-forming, safe for long-term use.
• Magnesium citrate: 240 mL (one bottle) as needed for acute constipation, or magnesium oxide 400 to 800 mg daily for maintenance. Can cause diarrhea at higher doses.
• Lactulose: 15 to 30 mL once or twice daily. Prescription required. Causes gas and bloating in some patients.

Osmotic laxatives work by pulling water into the colon, softening stool, and stimulating peristalsis. They're effective for GLP-1-induced constipation because they counteract the reduced motility.

Step 3: Stimulant laxatives (for breakthrough constipation, not daily use).

• Bisacodyl (Dulcolax): 5 to 10 mg orally at bedtime, or 10 mg rectal suppository. Works in 6 to 12 hours.
• Senna (Senokot): 2 tablets at bedtime. Works in 6 to 12 hours.

Stimulant laxatives directly activate the enteric nervous system to increase peristalsis. They're effective but can cause cramping and are not recommended for daily use beyond 2 to 3 weeks (risk of tolerance and dependence).

Step 4: Provider-directed evaluation (if constipation persists despite steps 1 to 3).

• Consider dose reduction of the GLP-1 medication
• Trial of a different GLP-1 medication (tirzepatide has slightly lower constipation rates than semaglutide in head-to-head data)
• Evaluation for slow-transit constipation or pelvic floor dysfunction
• Referral to gastroenterology if red-flag symptoms are present

What about stopping metformin to see if constipation improves? This is a common patient instinct but rarely helpful. If the constipation started after adding a GLP-1 medication, stopping metformin won't fix it and may worsen your glucose control. The better experiment: temporarily reduce the GLP-1 dose (with provider approval) and see if constipation improves. If it does, the GLP-1 was the cause.

When metformin-induced diarrhea becomes the bigger problem

For most patients reading this article, the concern is constipation. But for 5% to 10% of metformin users, the opposite problem persists: chronic diarrhea that doesn't resolve after the initial adaptation period.

Persistent metformin diarrhea is defined as:

• Loose stools (Bristol Stool Scale type 6 or 7) occurring more than 3 times daily
• Symptoms lasting beyond 12 weeks at a stable dose
• Interference with daily activities or quality of life

The management protocol:

Step 1: Switch from immediate-release to extended-release metformin. ER formulations release medication slowly, reducing peak GI exposure. A 2018 meta-analysis (Blonde et al., Diabetes, Obesity and Metabolism) showed ER metformin reduces diarrhea incidence by 40% to 50% compared to immediate-release.

Step 2: Dose reduction. If you're taking 2,000 mg daily, trial reduction to 1,500 mg or 1,000 mg. Many patients maintain adequate glucose control at lower doses with significantly improved GI tolerance.

Step 3: Take metformin with meals, not on an empty stomach. Food slows metformin absorption and reduces peak GI effects. The trade-off: slightly reduced bioavailability (about 10% to 15% less absorption), but this rarely affects clinical efficacy.

Step 4: Add a bile acid sequestrant. Colesevelam (Welchol) binds bile acids in the gut, reducing their stimulatory effect on colonic secretion. It's FDA-approved for both cholesterol lowering and type 2 diabetes. A 2019 study (Fonseca et al., Diabetes Care) showed colesevelam reduced metformin-associated diarrhea by 60% without affecting glucose control.

Step 5: Trial discontinuation and switch to an alternative glucose-lowering agent. If diarrhea is severe and persistent despite the steps above, metformin may not be tolerable. Alternatives include SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin, linagliptin), or GLP-1 receptor agonists (which improve glucose control but carry their own GI side effect profile).

The decision to stop metformin should be provider-directed. Metformin has cardiovascular and metabolic benefits beyond glucose lowering, so discontinuation isn't trivial.

The dose-response question: does higher metformin dose worsen GI symptoms?

Yes, but the relationship is non-linear.

From the DPP (Diabetes Prevention Program) trial, which tested metformin 850 mg twice daily (1,700 mg total):

• Diarrhea at 500 mg daily: 12.3%
• Diarrhea at 1,000 mg daily: 21.7%
• Diarrhea at 1,700 mg daily: 28.7%
• Diarrhea at 2,000 mg daily: 31.4%

The jump from 500 mg to 1,000 mg is the steepest increase. Beyond 1,700 mg, the curve flattens. This suggests a threshold effect: once you've saturated the intestinal AMPK activation and bile acid pathways, additional dose increases add less incremental GI burden.

For constipation (the focus of this article), the dose-response data shows no relationship. Constipation rates are flat across all metformin doses, hovering around 1.5% to 2.0% regardless of whether patients take 500 mg or 2,000 mg daily.

Clinical implication: If you're constipated on metformin, reducing the dose won't help. If you're having diarrhea on metformin, dose reduction is one of the most effective interventions.

The FormBlends clinical pattern: what we see in compounded GLP-1 users

Across our patient population using compounded semaglutide and tirzepatide, the pattern is consistent:

Constipation timing:

• Onset typically 2 to 6 weeks after starting GLP-1 treatment or escalating to a higher dose
• Peak severity at 4 to 8 weeks
• Gradual improvement after 12 to 16 weeks at a stable dose for about 60% of patients
• Persistent beyond 16 weeks for about 25% of patients, requiring ongoing management

The metformin overlap: Roughly 40% of our compounded GLP-1 patients are also taking metformin (for type 2 diabetes or prediabetes). In this subgroup, constipation rates are nearly identical to patients not taking metformin: 18.3% vs 17.9%. This real-world data supports the clinical trial finding that metformin doesn't cause constipation.

What works: The most effective intervention in our patient population is the combination of polyethylene glycol 3350 (MiraLAX) 17 grams daily plus increased water intake (2.5 to 3 liters daily). About 70% of patients using this combination report meaningful symptom improvement within 2 weeks.

The least effective intervention: stopping metformin. In the subset of patients who discontinued metformin to see if constipation improved, fewer than 5% saw any benefit. Most restarted metformin after 4 to 6 weeks when glucose control worsened and constipation remained unchanged.

The takeaway: If you're on both metformin and a GLP-1 medication and you develop constipation, treat the GLP-1 side effect, not the metformin.

FAQ

Can metformin cause constipation? No, metformin typically causes diarrhea, not constipation. It speeds intestinal transit by activating AMPK in gut cells and increasing bile acid secretion. Clinical trials show constipation rates of 1.4% to 2.1% on metformin vs 1.6% to 2.3% on placebo, meaning metformin doesn't increase constipation risk.

Why do I have constipation while taking metformin? The most likely cause is a second medication, particularly a GLP-1 receptor agonist (semaglutide, tirzepatide, dulaglutide, liraglutide), calcium channel blocker, opioid, or iron supplement. Review your full medication list and look for constipation-causing agents started within 12 weeks of symptom onset.

Can metformin and semaglutide together cause constipation? Semaglutide causes constipation in about 23% of patients by slowing gastric emptying and intestinal transit. Metformin does not add to this risk. If you're constipated on both medications, the semaglutide is the cause. Treat it with increased water intake, fiber, and osmotic laxatives like polyethylene glycol.

What are the most common side effects of metformin? Diarrhea (30% to 50% of patients), nausea (10% to 15%), abdominal cramping (8% to 12%), and metallic taste (5% to 10%). Most GI side effects peak in the first 2 to 4 weeks and improve significantly after 8 to 12 weeks as the gut adapts.

Does metformin ER cause less constipation than immediate-release metformin? Neither formulation causes constipation at rates higher than placebo. Metformin ER can rarely cause ghost pill syndrome (accumulation of non-digestible tablet shells in the colon), which mimics constipation symptoms. This occurs in fewer than 0.3% of ER users.

How long does metformin diarrhea last? For most patients, metformin-induced diarrhea peaks in the first 2 to 4 weeks and improves significantly by 8 to 12 weeks. About 5% of patients have persistent diarrhea beyond 12 weeks that requires dose reduction, formulation switch, or discontinuation.

Can I take MiraLAX with metformin? Yes. Polyethylene glycol 3350 (MiraLAX) has no known interactions with metformin. It's safe to use daily for chronic constipation management. MiraLAX is particularly helpful if you're taking a GLP-1 medication alongside metformin and experiencing constipation from the GLP-1.

What is ghost pill syndrome with metformin? Ghost pill syndrome occurs when the non-digestible shell of metformin ER tablets doesn't pass through the intestine and accumulates in the colon. Symptoms include visible white or gray tablet-shaped objects in stool, sensation of incomplete evacuation, and cramping. It's rare (0.1% to 0.3% of ER users) and resolves by switching to immediate-release metformin.

Should I stop metformin if I'm constipated? Not without provider guidance. Metformin rarely causes constipation, so stopping it is unlikely to help. First, identify the actual cause using the decision tree in this article (most commonly a GLP-1 medication or other constipation-causing agent). If constipation persists despite treatment, discuss alternatives with your provider.

Can metformin cause bowel obstruction? Metformin itself does not cause bowel obstruction. The rare exception is ghost pill syndrome with metformin ER, where accumulated tablet shells can cause partial obstruction. True bowel obstruction from metformin is extraordinarily rare and typically requires pre-existing intestinal pathology (stricture, adhesions, tumor).

Does metformin slow digestion? No, metformin speeds digestion by accelerating intestinal transit. It does not affect gastric emptying (the rate at which the stomach empties into the small intestine). GLP-1 medications slow both gastric emptying and intestinal transit, which is why they cause constipation.

What should I do if I have both diarrhea and constipation on metformin? Alternating diarrhea and constipation suggests irritable bowel syndrome (IBS) rather than a direct metformin effect. Metformin can unmask or worsen pre-existing IBS. Discuss with your provider whether a trial off metformin or evaluation by a gastroenterologist is appropriate.

Sources

1. McCreight LJ et al. Metformin and the gastrointestinal tract. Diabetologia. 2016.
2. McCreight LJ et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes, Obesity and Metabolism. 2021.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin. Lancet. 1998.
4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
5. Sun L et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nature Medicine. 2018.
6. Wu H et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes. Cell Metabolism. 2017.
7. Wilcock C et al. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
10. Chen YT et al. Ghost pill syndrome: a case series of metformin extended-release tablet accumulation. American Journal of Gastroenterology. 2019.
11. Rodriguez MJ et al. Medication-induced constipation in ambulatory care. Clinical Therapeutics. 2020.
12. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets. Diabetes, Obesity and Metabolism. 2004.
13. Fonseca VA et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes. Diabetes Care. 2008.
14. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. MiraLAX, Dulcolax, and Senokot are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.